Kineta (KANT) 10-Q 7 Aug 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 05, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Trading Symbol	PTI
Entity Registrant Name	PROTEOSTASIS THERAPEUTICS, INC.
Entity Central Index Key	0001445283
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		51,128,976
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Address, State or Province	Massachusetts
Entity File Number	001-37695
Entity Tax Identification Number	208436652
Entity Address, Address Line One	80 Guest Street, Suite 500
Entity Address, City or Town	Boston
Entity Address, Postal Zip Code	02135
City Area Code	617
Local Phone Number	225-0096

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 28,636	$ 28,810
Short-term investments	59,385	89,569
Prepaids and other current assets	3,066	2,481
Total current assets	91,087	120,860
Operating lease, right-of-use asset	13,246	13,849
Property and equipment, net	513	605
Other assets	75
Restricted cash	828	828
Total assets	105,749	136,142
Current liabilities:
Accounts payable	3,160	1,884
Accrued expenses	6,863	5,661
Operating lease liabilities	1,104	1,056
Total current liabilities	11,127	8,601
Derivative liability	3	3
Operating lease liabilities, net of current portion	12,634	13,196
Total liabilities	23,764	21,800
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of June 30, 2019 and December 31, 2018
Common stock, $0.001 par value; 125,000,000 shares authorized; 51,099,307 and 50,808,422 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively	51	51
Additional paid-in capital	393,872	391,825
Accumulated other comprehensive income	33	1
Accumulated deficit	(311,971)	(277,535)
Total stockholders’ equity	81,985	114,342
Total liabilities and stockholders’ equity	$ 105,749	$ 136,142

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	51,099,307	50,808,422
Common stock, shares outstanding	51,099,307	50,808,422

Condensed Statements of Operati

Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Revenue		$ 843	$ 5,000	$ 1,785
Operating expenses:
Research and development	$ 16,925	12,604	33,072	21,004
General and administrative	3,682	3,957	7,626	7,780
Total operating expenses	20,607	16,561	40,698	28,784
Loss from operations	(20,607)	(15,718)	(35,698)	(26,999)
Interest income	297	194	654	359
Other income, net	292	46	608	136
Net loss	$ (20,018)	$ (15,478)	$ (34,436)	$ (26,504)
Net loss per share—basic and diluted	$ (0.39)	$ (0.43)	$ (0.67)	$ (0.75)
Weighted average common shares outstanding—basic and diluted	51,097,456	36,009,109	51,037,514	35,245,796
Other comprehensive income (loss):
Unrealized gain (loss) on investments	$ 15	$ 16	$ 32	$ (10)
Comprehensive loss	$ (20,003)	$ (15,462)	$ (34,404)	$ (26,514)

Condensed Statements of Stockho

Condensed Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	ATM Program [Member]	Common Stock [Member]	Common Stock [Member]ATM Program [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]ATM Program [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2017	$ 68,808		$ 35		$ 285,583		$ (2)	$ (216,808)
Beginning balance, shares at Dec. 31, 2017			34,416,088
Exercise of stock options	21				21
Exercise of stock options, shares			8,775
Stock-based compensation expense	1,841				1,841
Issuance of common stock for payment of consulting services	534				534
Issuance of common stock for payment of consulting services, shares			94,107
Issuance of common stock pursuant to employee stock purchase plan	25				25
Issuance of common stock pursuant to employee stock purchase plan, shares			6,114
Issuance of common stock related to at-the-market offering program, net		$ 10,513		$ 2		$ 10,511
Issuance of common stock related to at-the-market offering program, net, shares				2,110,818
Impact of adoption of ASC 606 | ASC 606 [Member]	1,105							1,105
Other comprehensive income (loss)	(10)						(10)
Net loss	(26,504)							(26,504)
Ending balance at Jun. 30, 2018	56,333		$ 37		298,515		(12)	(242,207)
Ending balance, shares at Jun. 30, 2018			36,635,902
Beginning balance at Dec. 31, 2017	68,808		$ 35		285,583		(2)	(216,808)
Beginning balance, shares at Dec. 31, 2017			34,416,088
Ending balance at Dec. 31, 2018	$ 114,342		$ 51		391,825		1	(277,535)
Ending balance, shares at Dec. 31, 2018	50,808,422		50,808,422
Beginning balance at Mar. 31, 2018	$ 60,129		$ 35		286,851		(28)	(226,729)
Beginning balance, shares at Mar. 31, 2018			34,482,574
Stock-based compensation expense	927				927
Issuance of common stock for payment of consulting services	226				226
Issuance of common stock for payment of consulting services, shares			42,510
Issuance of common stock related to at-the-market offering program, net	10,513		$ 2		10,511
Issuance of common stock related to at-the-market offering program, net, shares			2,110,818
Other comprehensive income (loss)	16						16
Net loss	(15,478)							(15,478)
Ending balance at Jun. 30, 2018	56,333		$ 37		298,515		(12)	(242,207)
Ending balance, shares at Jun. 30, 2018			36,635,902
Beginning balance at Dec. 31, 2018	$ 114,342		$ 51		391,825		1	(277,535)
Beginning balance, shares at Dec. 31, 2018	50,808,422		50,808,422
Ending balance at Mar. 31, 2019	$ 100,967		$ 51		392,851		18	(291,953)
Ending balance, shares at Mar. 31, 2019			51,043,158
Beginning balance at Dec. 31, 2018	$ 114,342		$ 51		391,825		1	(277,535)
Beginning balance, shares at Dec. 31, 2018	50,808,422		50,808,422
Exercise of stock options	$ 3				3
Exercise of stock options, shares	2,543		2,543
Stock-based compensation expense	$ 1,749				1,749
Issuance of common stock for payment of consulting services	242				242
Issuance of common stock for payment of consulting services, shares			102,302
Issuance of common stock pursuant to employee stock purchase plan	$ 53				53
Issuance of common stock pursuant to employee stock purchase plan, shares	2,543		22,615
Vesting of restricted stock units, shares			163,425
Other comprehensive income (loss)	$ 32						32
Net loss	(34,436)							(34,436)
Ending balance at Jun. 30, 2019	$ 81,985		$ 51		393,872		33	(311,971)
Ending balance, shares at Jun. 30, 2019	51,099,307		51,099,307
Beginning balance at Mar. 31, 2019	$ 100,967		$ 51		392,851		18	(291,953)
Beginning balance, shares at Mar. 31, 2019			51,043,158
Stock-based compensation expense	949				949
Issuance of common stock for payment of consulting services	72				72
Issuance of common stock for payment of consulting services, shares			56,149
Other comprehensive income (loss)	15						15
Net loss	(20,018)							(20,018)
Ending balance at Jun. 30, 2019	$ 81,985		$ 51		$ 393,872		$ 33	$ (311,971)
Ending balance, shares at Jun. 30, 2019	51,099,307		51,099,307

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities:
Net loss	$ (34,436)	$ (26,504)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	704	1,094
Amortization (accretion) of short-term investments	(614)	(129)
Stock-based compensation expense	1,749	1,841
Stock issued for consulting services	242	534
Change in fair value of derivative liability		(22)
Loss on disposal of property and equipment		41
Changes in operating assets and liabilities:
Prepaids and other current assets	(585)	(761)
Other assets	(75)	18
Accounts payable	1,276	(258)
Accrued expenses	1,202	402
Deferred revenue		(3)
Operating lease liabilities	(514)	(1,118)
Net cash used in operating activities	(31,051)	(24,865)
Cash flows from investing activities:
Purchases of short-term investments	(43,170)	(24,883)
Proceeds received from maturities of short-term investments	74,000	28,850
Purchases of property and equipment	(9)	(406)
Net cash provided by investing activities	30,821	3,561
Cash flows from financing activities:
Proceeds from issuance of common stock related to at-the-market offering program, net		10,513
Proceeds from exercise of stock options	3	21
Proceeds from issuance of common stock pursuant to employee stock purchase plan	53	25
Deferred offering costs		(171)
Net cash provided by financing activities	56	10,388
Net increase (decrease) in cash, cash equivalents and restricted cash	(174)	(10,916)
Cash, cash equivalents and restricted cash at beginning of period	29,638	31,674
Cash, cash equivalents and restricted cash at end of period	$ 29,464	20,758
Supplemental disclosure of non-cash investing and financing activities:
Deferred offering costs included in accrued expenses		25
Addition of Operating Lease Right-Of-Use Asset [Member]
Supplemental disclosure of non-cash investing and financing activities:
Addition of operating lease, right-of-use asset		$ 15,304

Nature of the Business

Nature of the Business	6 Months Ended
	Jun. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of the Business	1. Nature of the Business Proteostasis Therapeutics, Inc. (the “Company”) was incorporated in Delaware on December 13, 2006. The Company is a clinical stage biopharmaceutical company committed to the discovery and development of novel therapeutics to treat cystic fibrosis (“CF”) and other diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. The Company focuses on identifying therapies that restore protein function. CF is a disease caused by defects in the function or abundance of cystic fibrosis transmembrane conductance regulator (“CFTR”). The Company’s CF focused pipeline consists of novel CFTR modulators including correctors, potentiators and amplifiers. Upon discovery of amplifiers, a novel class of CFTR modulators, the Company has exploited its novel mechanism of action as a drug screening tool and has subsequently identified correctors and potentiators to be developed as part of combination therapies. Investigational agents representative of all three classes of CFTR modulators are currently in clinical development and include PTI-801, a third generation CFTR corrector, PTI-808, a CFTR potentiator, and PTI-428, a CFTR amplifier. The Company is pursuing proprietary dual combination of PTI-801 and PTI-808, and triple combination of PTI-801, PTI-808 and PTI-428 as product opportunities. The Company is developing and, if approved, intends to commercialize their own proprietary combination therapies for CF patients who have at least one F508del mutation, representing the majority of the patient population. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. In accordance with ASC 205-40, Going Concern . The Company has incurred losses and negative cash flows from operations since its inception. As of June 30, 2019, the Company had an accumulated deficit of $312.0 million. During the six months ended June 30, 2019, the Company incurred losses of $34.4 million and used $31.1 million of cash in operations. $88.0 million will be sufficient to fund its operating expenses and capital requirements, based upon its current operating plan, for at least 12 months from the date that these financial statements are issued. In May 2019, the Company entered into a sales agreement with H.C. Wainwright & Co., LLC (“HCW”) with respect to an ATM offering program under which the Company may issue and sell, from time to time at its sole discretion, shares of its common stock, in an aggregate offering amount of up to $56.6 million (the “HCW ATM program”). HCW acts as the Company’s sales agent and will use commercially reasonable efforts to sell shares of common stock from time to time, based upon instruction form the Company. Common stock will be sold at prevailing market prices at the time of the sale; and as a result, prices may vary. The Company will pay HCW up to 3% of the gross proceeds from any common stock sold through the sales agreement. As of June 30, 2019, the Company has not sold any shares of its common stock under the HCW ATM program. In the fourth quarter of 2018, the Company completed a follow-on public offering whereby the Company sold 12,650,000 shares of common stock at a public offering price of $6.75 per share, which included 1,650,000 shares issued pursuant to the exercise by the underwriters of their option to purchase additional shares of common stock. The Company received net proceeds of $80.1 million, after deducting underwriting discounts and commissions and other offering expenses. In March 2018, the Company entered into a sales agreement with Leerink Partners LLC (“Leerink”) with respect to an at-the-market (“ATM”) offering program under which the Company could have issued and sold, from time to time at its sole discretion, shares of its common stock, in an aggregate offering amount of up to $50.0 million. As of March 31, 2019, the Company had sold an aggregate of 3,475,166 shares of its common stock for total net proceeds of approximately $21.6 million under the ATM program. On March 28, 2019 the Company delivered a notice of termination of the ATM offering program to Leerink, effective as of April 7, 2019.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Unaudited Interim Financial Information The condensed balance sheet as of December 31, 2018 was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed financial statements as of June 30, 2019 and for the three and six months ended June 30, 2019 are unaudited and have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 8, 2019. In the opinion of management, all adjustments, consisting only of normal recurring adjustments as necessary, for the fair statement of the Company’s financial position as of June 30, 2019, results of its operations for the three and six months ended June 30, 2019, and cash flows for the six months ended June 30, 2019 have been made. The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2019. Summary of Significant Accounting Policies The Company’s significant accounting policies, which are disclosed in the audited consolidated financial statements for the year ended December 31, 2018 and the notes thereto are included in the Company’s Annual Report on Form 10-K that was filed with the SEC on March 8, 2019. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual for research and development expenses and the valuation of common stock, and the derivative liability. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. Revenue Recognition Effective January 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers . Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. . The Company enters into licensing agreements which are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: nonrefundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above; b) the transaction price under step (iii) above; and c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. The Company uses judgment to determine whether milestones or other variable consideration should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In developing the stand-alone price for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the stand-alone selling price for performance obligations by evaluating whether changes in the key assumptions used to determine the stand-alone selling prices will have a significant effect on the allocation of transaction price between multiple performance obligations. The Company records any amounts received prior to satisfying the revenue recognition criteria as deferred revenue. Amounts recognized as revenue, but not yet received or invoiced are recorded as current assets. Exclusive Licenses If the license to the Company’s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from nonrefundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. Research and Development Services The promises under the Company’s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. As the provision of research and development services is a part of the Company’s central operations, when the Company is principally responsible for the performance of these services under the agreements, the Company recognizes revenue on a gross basis for research and development services in accordance with the ASC 606 framework described above. Customer Options If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. Milestone Payments At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones or other variable consideration should be included in the transaction price. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. Royalties For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. For a complete discussion of accounting for collaboration revenues, see Note 8 - Significant Agreements Recently Issued and Adopted Accounting Pronouncements In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting Recently Issued Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement

Short-Term Investments

Short-Term Investments	6 Months Ended
	Jun. 30, 2019
Cash Cash Equivalents And Short Term Investments [Abstract]
Short-Term Investments	3. Short-Term Investments The following table summarizes the Company’s short-term investments as of June 30, 2019 and December 31, 2018 (in thousands): June 30, 2019 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S government-sponsored enterprise securities $ 48,869 $ 26 $ (1 ) $ 48,894 U.S. treasury securities 10,483 8 — 10,491 $ 59,352 $ 34 $ (1 ) $ 59,385 December 31, 2018 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S government-sponsored enterprise securities $ 41,478 $ 2 $ (3 ) $ 41,477 U.S. treasury securities 48,090 3 (1 ) 48,092 $ 89,568 $ 5 $ (4 ) $ 89,569 The Company did not have any realized gains or losses on its short-term investments for the three and six months ended June 30, 2019 and 2018 2018

Fair Value of Financial Assets

Fair Value of Financial Assets and Liabilities	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value of Financial Assets and Liabilities	4. Fair Value of Financial Assets and Liabilities The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): Fair Value Measurements as of June 30, 2019 using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 27,732 $ — $ — $ 27,732 Short-term investments: U.S. government-sponsored enterprise securities — 48,894 — 48,894 U.S. treasury securities — 10,491 — 10,491 $ 27,732 $ 59,385 $ — $ 87,117 Liabilities: Derivative liability $ — $ — $ 3 $ 3 Fair Value Measurements as of December 31, 2018 using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 26,806 $ — $ — $ 26,806 U.S. treasury securities — 500 — 500 Short-term investments: U.S. government-sponsored enterprise securities — 41,477 — 41,477 U.S. treasury securities — 48,092 — 48,092 $ 26,806 $ 90,069 $ — $ 116,875 Liabilities: Derivative liability $ — $ — $ 3 $ 3 During the periods ended June 30, 2019 and December 31, 2018, there were no transfers between Level 1, Level 2 and Level 3. The derivative liability relates to a cash settlement option associated with the change of control provision in the Company’s Cystic Fibrosis Foundation, Inc. (“CFF”) agreement, which meets the definition of a derivative. The fair value of the derivative liability is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative instrument was determined using the Monte-Carlo simulation analysis. In determining the fair value of the derivative liability, the inputs impacting fair value include the fair value of the Company’s common stock, expected term of the derivative instrument, expected volatility of the common stock price, risk-free interest rate, expected sales-based milestone payments, discount rate, probability of a change of control event, and the probability that the counterparty would elect to accept the alternative cash payment in lieu of its right to the future sales-based milestone payments. The fair value of the derivative liability was not material at June 30, 2019 and December 31, 2018.

Prepaids and Other Current Asse

Prepaids and Other Current Assets	6 Months Ended
	Jun. 30, 2019
Prepaid Expense And Other Assets Current [Abstract]
Prepaids and Other Current Assets	5. Prepaids and Other Current Assets Prepaids and other current assets consisted of the following (in thousands): June 30, December 31, 2019 2018 Prepaid clinical, manufacturing and scientific expenses $ 1,741 $ 1,660 Prepaid insurance expenses 691 108 Other prepaid expenses and other current assets 634 713 $ 3,066 $ 2,481

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2019
Payables And Accruals [Abstract]
Accrued Expenses	6. Accrued Expenses Accrued expenses consisted of the following (in thousands): June 30, December 31, 2019 2018 Accrued payroll and related expenses $ 1,992 $ 2,746 Accrued research and development expenses 4,349 1,965 Accrued professional fees 443 799 Accrued other 79 151 $ 6,863 $ 5,661

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	7. Stock-Based Compensation 2016 Stock Option and Incentive Plan On February 3, 2016, the Company’s stockholders approved the 2016 Stock Option and Incentive Plan (the “2016 Plan”), which became effective on February 9, 2016. The 2016 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards and other stock-based awards. The number of shares initially reserved for issuance under the 2016 Plan was 1,581,839 shares. The number of shares of common stock that may be issued under the 2016 Plan will automatically increase on each January 1, beginning on January 1, 2017, by the lesser of 3% of the shares of the Company’s common stock outstanding on the immediately preceding December 31 or an amount determined by the Company’s board of directors or the compensation committee of the board of directors. The shares of common stock underlying any awards that are forfeited, canceled, repurchased or are otherwise terminated by the Company under the 2016 Plan and the 2008 Equity Incentive Plan, as amended (the “2008 Plan”) will be added back to the shares of common stock available for issuance under the 2016 Plan. As of June 30, 2019, the total number of shares reserved under the 2016 Plan and 2008 Plan was 5,351,340 and the Company had 752,490 shares available for future issuance under the 2016 Plan. 2016 Employee Stock Purchase Plan On February 3, 2016, the Company’s stockholders approved the 2016 Employee Stock Purchase Plan (the “2016 ESPP”), which became effective in connection with the completion of the Company’s initial public offering. A total of 138,757 shares of common stock were initially reserved for issuance under this plan. In addition, the number of shares of common stock that may be issued under the 2016 ESPP will automatically increase on each January 1, beginning on January 1, 2017 and ending on January 1, 2026, by the lesser of (i) 138,757 shares of common stock, (ii) 1% of the Company’s shares of common stock outstanding on the immediately preceding December 31 or (iii) an amount determined by the Company’s board of directors or the compensation committee of the board of directors. During the six months ended June 30, 2019, 22,615 shares of common stock were issued pursuant to the 2016 ESPP. As of June 30, 2019, the total number of shares reserved under the 2016 ESPP was 502,681 shares. The Company recognized less than $0.1 million of stock-based compensation during the three and six months ended June 30, 2019 related to the 2016 ESPP. Bonus Restricted Stock Units (RSUs) On February 1, 2018, the Company’s board approved executive bonuses for the year ended December 31, 2017 and elected payment to be made through a grant of an equivalent number of RSUs based on the February 1, 2018 closing share price of the Company’s common stock. The grants did not meet the criteria for liability classification as there was a fixed number of shares to be issued and there is no variability in the number of shares which had been granted. The requisite service period for the awards was from February 1, 2018 to February 1, 2019 (the vesting period). The Company recognized employee stock-based compensation expense for the bonus RSU grants on a straight-line basis over the vesting period of the awards. On February 1, 2019, the outstanding RSUs fully vested and were converted to 163,425 shares of common stock. As of June 30, 2019, there were no RSUs outstanding and less than $0.1 million of expense was recognized for the six months ended June 30, 2019. As of June 30, 2018, there were no RSUs vested and $0.1 million and $ .2 The following table summarizes the Company’s RSU activity for the six months ended June 30, 2019: Number of Shares Weighted Average Grant Date Fair Value Unvested balance at December 31, 2018 163,425 $ 3.20 Granted — — Vested (163,425 ) 3.20 Forfeited — — Unvested balance at June 30, 2019 — $ — Stock-Based Compensation Stock-based compensation expense, including shares issued to a nonemployee for consulting services, was classified in the statements of operations as follows (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2019 2018 2019 2018 Research and development $ 399 $ 412 $ 769 $ 775 General and administrative 622 741 1,222 1,600 $ 1,021 $ 1,153 $ 1,991 $ 2,375 The following table summarizes the Company’s stock option activity for the six months ended June 30, 2019 (in thousands except share and per share amounts): Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (Years) Outstanding at December 31, 2018 3,158,676 $ 5.93 7.53 $ 471 Granted 1,497,200 4.08 Exercised (2,543 ) 1.09 Forfeited (54,483 ) 8.01 Outstanding at June 30, 2019 4,598,850 $ 5.30 7.88 $ — Exercisable at June 30, 2019 2,126,163 $ 6.20 6.77 $ — Vested and expected to vest at June 30, 2019 4,515,600 $ 5.36 7.99 $ — The grant date fair value of options granted during the period was $4.4 million, or $2.92 per share on a weighted-average basis and will be recognized as compensation expense over the requisite service period of four years. There were 2,543 shares of common stock issued upon the exercise of outstanding stock options for the six months ended June 30, 2019, resulting in total proceeds of less than $0.1 million. In accordance with Company policy, the shares were issued from the shares reserved for issuance under the stock plans described above. The intrinsic value of options exercised for the six months ended June 30, 2019 was less than $0.1 million. As of June 30, 2019, there was $6.9 million of unrecognized compensation cost related to employee and nonemployee unvested stock options granted under the 2016 Plan, which is expected to be recognized over a weighted-average remaining service period of 2.65 years. Stock compensation costs have not been capitalized by the Company. Prior to 2013, the Company issued options to purchase 203,964 shares of common stock to nonemployees, primarily members of the Company’s scientific advisory board, that vest upon the achievement of specified development and clinical milestones. As of June 30, 2019, options for the purchase of 83,250 shares held by nonemployees remained unvested, pending achievement of the specified milestones.

Significant Agreements

Significant Agreements	6 Months Ended
	Jun. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Significant Agreements	8. Significant Agreements Genentech In December 2018, the Company entered into a Technology Transfer and License Agreement (the “Genentech Agreement”) with Genentech, Inc. (“Genentech”) under which the Company granted Genentech an exclusive worldwide license for technology and materials relating to potential therapeutic small molecule modulators of an undisclosed target within the proteostasis network. The rights do not include CFTR modulators and are unrelated to the Company’s investigational medicines or other ongoing research programs in cystic fibrosis. In connection with the terms of the Genentech Agreement, the Company is entitled to a nonrefundable cash payment of $5.0 million following the successful completion of the technology and materials transfer to Genentech and future milestone payments in the aggregate of approximately $96.0 million upon the achievement of specified development, regulatory and commercial milestones. In addition, Genentech is obligated to pay the Company tiered royalties in the low single-digits based on net sales of products covered by the licenses granted under the Genentech Agreement. There are no cancellation, termination or refund provisions in the Genentech Agreement that contain material financial consequences to the Company. Unless earlier terminated, the Genentech Agreement continues in full force and effect until the passing or expiration of all royalty payment obligations. Reciprocal termination rights under the agreement include termination for breach and termination for bankruptcy. Genentech may terminate the Genentech Agreement in its entirety for convenience upon thirty days’ notice to the Company. The Company evaluated the Genentech Agreement in accordance with the provisions of ASC 606. The Company’s obligations under the Genentech Agreement are the following promises: (i) exclusive license to certain intellectual property associated with a specific target and (ii) technology and materials transfer related to the intellectual property underlying the licensed technology. The Company determined that the exclusive license is not distinct from the associated technology and materials transfer because the customer cannot benefit from or utilize the license without the technology and materials transfer. Specifically, the Company concluded that the exclusive license is not capable of being distinct from the associated technology and materials transfer because Genentech does not have the knowledge or expertise to fully exploit potential product candidates without the accompanying technology and materials provided pursuant to the transfer and no other third party can perform the transfer due to the Company’s proprietary knowledge and specialized expertise with respect to the licensed intellectual property. Accordingly, the Company concluded that these promises should be combined into a single performance obligation (the “License and Transfer Performance Obligation”). As of June 30, 2019, the Company has measured the transaction price solely in reference to the $5.0 million payment due upon receipt of notice from Genentech regarding the satisfactory completion of the technology and materials transfer. None of the variable consideration payable under the arrangement has been included in the transaction price as of June 30, 2019. Through June 30, 2019, the Company has not achieved any research, development, regulatory or commercial milestones or earned any royalties under the Genentech Agreement. The Company utilizes the most likely amount method to estimate the amount of research, development and regulatory milestone payments to be received. As part of the evaluation for the research and development milestone payments, the Company considers several factors, including the stage of research and development of the compounds included in the arrangement, the risk associated with the remaining research and development work required to achieve the milestone and the Company’s level of involvement in the research and development activities. None of the variable consideration payable has been included in the transaction price through June 30, 2019. Regulatory milestone payments are triggered upon the first commercial sale following receipt of regulatory approval from the FDA or other global regulatory authorities; therefore, such amounts will be excluded from the transaction price until the associated regulatory approval is received. The commercial milestone payments and royalties are subject to the royalty recognition constraint whereby such amounts will be recognized as revenue upon the later of: (i) when the related sales occur or (ii) when the performance obligation to which some or all of the payment has been allocated has been satisfied, or partially satisfied, because the exclusive license is deemed to be the sole or predominant item to which the payments relate. As all performance obligations have been satisfied the Company will recognize royalty revenue at the date the sales occur. The Company did not adjust the promised amount of consideration for the effects of a significant financing component because the Company expects that the period between when the promised goods and services are transferred and when the customer pays for those goods and services will be one year or less. There were no changes in the transaction price for the six months ended June 30, 2019. The Company allocated the transaction price of $5.0 million to the sole identified performance obligation in its entirety. Amounts allocated to the combined performance obligation comprised of the exclusive license and the associated technology and materials transfer will be recognized as revenue at a point in time based on the date on which Genentech provides notice regarding the satisfactory completion of the technology and materials transfer. Upon the successful execution of the technology and materials transfer, control is considered to be transferred to both the exclusive license and the technology and materials transfer promises due primarily to the payment contingency and timing of the conveyance of risks and rewards of ownership. In February 2019, the Company completed the technology and materials transfer and received the upfront payment of $5.0 million. The Company recognized revenue of $5.0 million for the six months ended June 30, 2019 as the technology and materials transfer has been completed. As of June 30, 2019, the Company did not have any receivables or deferred revenue related to the Genentech Agreement because neither had any payments under the arrangement become due nor had the underlying performance obligation been satisfied. Astellas In November 2014, the Company entered into the Collaborative Research, Development, Commercialization and License Agreement (the “Astellas Agreement”) with Astellas Pharma Inc. (“Astellas”). The focus of the Astellas Agreement was to identify, develop and commercialize therapeutic candidates relating to the Unfolded Protein Response (“UPR”) pathway. Under terms of the Astellas Agreement, Astellas purchased from the Company convertible promissory notes totaling $5.0 million with terms consistent with those of other investors that purchased convertible promissory notes issued during 2014. In addition, the Company was eligible to receive research funding support, based on the establishment of an annual research budget, and future research, development and sales milestone payments of up to $398.5 million, as well as tiered royalty payments ranging in the mid-single-digit to low double-digit percentages of net sales, as defined in the agreement. Under the agreement, the companies conducted research during the initial research term, which was approximately 3½ years, to identify lead compounds for clinical development. At the end of the research term, Astellas, in its sole discretion, could designate a development compound and make a milestone payment to the Company. The Company had the right, but not the obligation, to co-develop the compound. If the Company did not exercise its option to co-develop the compound, Astellas had an exclusive right to the compound and sole right and responsibility for the development of the compound . As of December 31, 2018, the Astellas Agreement was complete and all of the Company’s performance obligations under the contract have been satisfied. The Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Astellas, is a customer. The Company identified the following material promises as of the most recent amendment in April 2018: (1) the research license; (2) the research services to be provided over the research term; and (3) participation in the Joint Research Committee (the “Committee”) to be provided over the research term of the agreement. The Company determined that the license and research services were not distinct from one another, as the license has limited value without the performance of the research and development activities. Participation in the Committee to oversee the research activities was determined to be quantitatively and qualitatively immaterial and therefore is excluded from performance obligations. As such, the Company determined that these promises should be combined into a single performance obligation. The Company evaluated the Astellas option right to designate a development compound, as described above, to determine whether it provides Astellas with a material right. The Company concluded that the option was not issued at a significant and incremental discount and Astellas has only the right to pursue negotiations for additional projects, and therefore does not provide a material right. As such, they are excluded from performance obligations at the inception of the arrangement. Revenue associated with the performance obligation was recognized as the research and development services were provided using an input method, according to the costs incurred as related to the research and development activities and the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurred over this period and in management’s judgment, was the best measure of progress towards satisfying the performance obligation. As of December 31, 2018, the research and development services related to this performance obligation were complete. The Company recognized $0.8 million and $1.8 million of revenue related to the Astellas Agreement for the three and six months ended June 30, 2018, respectively.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes The Company did not record a federal or state income tax benefit for its losses for the three and six months ended June 30, 2019 and 2018 due to the conclusion that a full valuation allowance is required against the Company’s deferred tax assets. All of the Company’s losses before income taxes were generated in the United States.

Net Loss per Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Net Loss per Share	10. Net Loss per Share Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts): For the Three Months Ended June 30, For the Six Months Ended June 30, 2019 2018 2019 2018 Numerator: Net loss $ (20,018 ) $ (15,478 ) $ (34,436 ) $ (26,504 ) Denominator: Weighted average number of common shares outstanding—basic and diluted 51,097,456 36,009,109 51,037,514 35,245,796 Net loss per share—basic and diluted $ (0.39 ) $ (0.43 ) $ (0.67 ) $ (0.75 ) The following common stock equivalents have been excluded from the computation of diluted weighted-average shares outstanding, because such securities had an antidilutive impact : June 30, 2019 2018 Options to purchase common stock 4,598,850 3,346,629 Restricted stock units — 183,506 4,598,850 3,530,135

Leases

Leases	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Leases	11. Leases The Company has an operating lease for office and laboratory space for its corporate headquarters in Boston, Massachusetts. The lease commenced in January 2018 and rent payments began in April 2018. This lease has a ten-year initial term with an option to extend for seven additional years. The lessee has the right to terminate the lease in the event of the inability to use the space due to substantial damage while the lessor has the right to terminate the lease for tenant’s default of lease financial obligations. Per the terms of the lease agreement, the Company does not have any residual value guarantees. In calculating the present value of the lease payments, the Company has utilized its incremental borrowing rate based on electing the original lease term to account for each lease component and its associated non-lease components as a single lease component. It has allocated all the contract consideration across lease components only. This may result in the initial and subsequent measurement of the balances of the right-of-use asset and lease liability for leases being greater than if the policy election was not applied. The Company’s real estate lease in Boston is considered a net lease, as the non-lease components (i.e. common area maintenance) are paid separately from rent based on actual costs incurred. Therefore, the non-lease components were not included in the right-of-use asset and liability and are reflected as an expense in the period incurred. The Company’s prior lease in Cambridge, Massachusetts expired in May 2018. As of June 30, 2019 and December 31, 2018, assets under operating lease were $13.2 million and $13.8 million, respectively. The elements of lease expense were as follows (in thousands): For the Three Months Ended June 30, 2019 2018 Lease cost Operating lease cost $ 459 $ 662 Variable lease cost (1) 179 163 Total lease cost $ 638 $ 825 For the Six Months Ended June 30, 2019 2018 Lease cost Operating lease cost $ 921 $ 1,322 Variable lease cost (1) 316 309 Total lease cost $ 1,237 $ 1,631 Other information Operating cash flows used for operating leases $ 836 $ 461 Operating lease liabilities arising from obtaining right-of-use assets $ 13,738 $ 14,746 Weighted-average remaining lease term 8.84 years 9.84 years Weighted-average discount rate 4.50 % 4.50 % (1) The variable lease costs for the three and six months ended June 30, 2019 and 2018 Future lease payments under no ncancelable leases as of June 30, 2019 (in thousands): Future Operating Lease Payments 2019 $ 851 2020 1,733 2021 1,780 2022 1,829 2023 1,880 Thereafter 8,757 Total lease payments 16,830 Less: imputed interest (3,092 ) Total operating lease liabilities $ 13,738

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Unaudited Interim Financial Information	Unaudited Interim Financial Information The condensed balance sheet as of December 31, 2018 was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed financial statements as of June 30, 2019 and for the three and six months ended June 30, 2019 are unaudited and have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 8, 2019. In the opinion of management, all adjustments, consisting only of normal recurring adjustments as necessary, for the fair statement of the Company’s financial position as of June 30, 2019, results of its operations for the three and six months ended June 30, 2019, and cash flows for the six months ended June 30, 2019 have been made. The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2019.
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies The Company’s significant accounting policies, which are disclosed in the audited consolidated financial statements for the year ended December 31, 2018 and the notes thereto are included in the Company’s Annual Report on Form 10-K that was filed with the SEC on March 8, 2019.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual for research and development expenses and the valuation of common stock, and the derivative liability. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition Effective January 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers . Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. . The Company enters into licensing agreements which are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: nonrefundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above; b) the transaction price under step (iii) above; and c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above. The Company uses judgment to determine whether milestones or other variable consideration should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In developing the stand-alone price for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the stand-alone selling price for performance obligations by evaluating whether changes in the key assumptions used to determine the stand-alone selling prices will have a significant effect on the allocation of transaction price between multiple performance obligations. The Company records any amounts received prior to satisfying the revenue recognition criteria as deferred revenue. Amounts recognized as revenue, but not yet received or invoiced are recorded as current assets. Exclusive Licenses If the license to the Company’s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from nonrefundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. Research and Development Services The promises under the Company’s collaboration and license agreements generally include research and development services to be performed by the Company on behalf of the collaboration partner. As the provision of research and development services is a part of the Company’s central operations, when the Company is principally responsible for the performance of these services under the agreements, the Company recognizes revenue on a gross basis for research and development services in accordance with the ASC 606 framework described above. Customer Options If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. Milestone Payments At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones or other variable consideration should be included in the transaction price. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. Royalties For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. For a complete discussion of accounting for collaboration revenues, see Note 8 - Significant Agreements
Recently Issued and Adopted Accounting Pronouncements	Recently Issued and Adopted Accounting Pronouncements In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting Recently Issued Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement
Derivative Liability	The derivative liability relates to a cash settlement option associated with the change of control provision in the Company’s Cystic Fibrosis Foundation, Inc. (“CFF”) agreement, which meets the definition of a derivative. The fair value of the derivative liability is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative instrument was determined using the Monte-Carlo simulation analysis. In determining the fair value of the derivative liability, the inputs impacting fair value include the fair value of the Company’s common stock, expected term of the derivative instrument, expected volatility of the common stock price, risk-free interest rate, expected sales-based milestone payments, discount rate, probability of a change of control event, and the probability that the counterparty would elect to accept the alternative cash payment in lieu of its right to the future sales-based milestone payments. The fair value of the derivative liability was not material at June 30, 2019 and December 31, 2018.

Short-Term Investments (Tables)

Short-Term Investments (Tables)	6 Months Ended
	Jun. 30, 2019
Cash Cash Equivalents And Short Term Investments [Abstract]
Summary of Short-Term Investments	The following table summarizes the Company’s short-term investments as of June 30, 2019 and December 31, 2018 (in thousands): June 30, 2019 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S government-sponsored enterprise securities $ 48,869 $ 26 $ (1 ) $ 48,894 U.S. treasury securities 10,483 8 — 10,491 $ 59,352 $ 34 $ (1 ) $ 59,385 December 31, 2018 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S government-sponsored enterprise securities $ 41,478 $ 2 $ (3 ) $ 41,477 U.S. treasury securities 48,090 3 (1 ) 48,092 $ 89,568 $ 5 $ (4 ) $ 89,569

Fair Value of Financial Asset_2

Fair Value of Financial Assets and Liabilities (Tables)	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): Fair Value Measurements as of June 30, 2019 using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 27,732 $ — $ — $ 27,732 Short-term investments: U.S. government-sponsored enterprise securities — 48,894 — 48,894 U.S. treasury securities — 10,491 — 10,491 $ 27,732 $ 59,385 $ — $ 87,117 Liabilities: Derivative liability $ — $ — $ 3 $ 3 Fair Value Measurements as of December 31, 2018 using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 26,806 $ — $ — $ 26,806 U.S. treasury securities — 500 — 500 Short-term investments: U.S. government-sponsored enterprise securities — 41,477 — 41,477 U.S. treasury securities — 48,092 — 48,092 $ 26,806 $ 90,069 $ — $ 116,875 Liabilities: Derivative liability $ — $ — $ 3 $ 3

Prepaids and Other Current As_2

Prepaids and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2019
Prepaid Expense And Other Assets Current [Abstract]
Schedule of Prepaids and Other Current Assets	Prepaids and other current assets consisted of the following (in thousands): June 30, December 31, 2019 2018 Prepaid clinical, manufacturing and scientific expenses $ 1,741 $ 1,660 Prepaid insurance expenses 691 108 Other prepaid expenses and other current assets 634 713 $ 3,066 $ 2,481

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2019
Payables And Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following (in thousands): June 30, December 31, 2019 2018 Accrued payroll and related expenses $ 1,992 $ 2,746 Accrued research and development expenses 4,349 1,965 Accrued professional fees 443 799 Accrued other 79 151 $ 6,863 $ 5,661

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Restricted Stock Unit Activity	The following table summarizes the Company’s RSU activity for the six months ended June 30, 2019: Number of Shares Weighted Average Grant Date Fair Value Unvested balance at December 31, 2018 163,425 $ 3.20 Granted — — Vested (163,425 ) 3.20 Forfeited — — Unvested balance at June 30, 2019 — $ —
Summary of Stock-Based Compensation Expense, Including Shares Issued to Nonemployee for Consulting Services	Stock-based compensation expense, including shares issued to a nonemployee for consulting services, was classified in the statements of operations as follows (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2019 2018 2019 2018 Research and development $ 399 $ 412 $ 769 $ 775 General and administrative 622 741 1,222 1,600 $ 1,021 $ 1,153 $ 1,991 $ 2,375
Summary of Stock Option Activity	The following table summarizes the Company’s stock option activity for the six months ended June 30, 2019 (in thousands except share and per share amounts): Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (Years) Outstanding at December 31, 2018 3,158,676 $ 5.93 7.53 $ 471 Granted 1,497,200 4.08 Exercised (2,543 ) 1.09 Forfeited (54,483 ) 8.01 Outstanding at June 30, 2019 4,598,850 $ 5.30 7.88 $ — Exercisable at June 30, 2019 2,126,163 $ 6.20 6.77 $ — Vested and expected to vest at June 30, 2019 4,515,600 $ 5.36 7.99 $ —

Net Loss per Share (Tables)

Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss per Share	Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts): For the Three Months Ended June 30, For the Six Months Ended June 30, 2019 2018 2019 2018 Numerator: Net loss $ (20,018 ) $ (15,478 ) $ (34,436 ) $ (26,504 ) Denominator: Weighted average number of common shares outstanding—basic and diluted 51,097,456 36,009,109 51,037,514 35,245,796 Net loss per share—basic and diluted $ (0.39 ) $ (0.43 ) $ (0.67 ) $ (0.75 )
Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted-average Shares Outstanding	The following common stock equivalents have been excluded from the computation of diluted weighted-average shares outstanding, because such securities had an antidilutive impact : June 30, 2019 2018 Options to purchase common stock 4,598,850 3,346,629 Restricted stock units — 183,506 4,598,850 3,530,135

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2019
Lessee Disclosure [Abstract]
Elements of Lease Expense	The elements of lease expense were as follows (in thousands): For the Three Months Ended June 30, 2019 2018 Lease cost Operating lease cost $ 459 $ 662 Variable lease cost (1) 179 163 Total lease cost $ 638 $ 825 For the Six Months Ended June 30, 2019 2018 Lease cost Operating lease cost $ 921 $ 1,322 Variable lease cost (1) 316 309 Total lease cost $ 1,237 $ 1,631 Other information Operating cash flows used for operating leases $ 836 $ 461 Operating lease liabilities arising from obtaining right-of-use assets $ 13,738 $ 14,746 Weighted-average remaining lease term 8.84 years 9.84 years Weighted-average discount rate 4.50 % 4.50 % (1) The variable lease costs for the three and six months ended June 30, 2019 and 2018
Schedule of Future Lease Payments under Noncancelable Leases	Future lease payments under no ncancelable leases as of June 30, 2019 (in thousands): Future Operating Lease Payments 2019 $ 851 2020 1,733 2021 1,780 2022 1,829 2023 1,880 Thereafter 8,757 Total lease payments 16,830 Less: imputed interest (3,092 ) Total operating lease liabilities $ 13,738

Nature of the Business - Additi

Nature of the Business - Additional Information (Detail) - USD ($)	Mar. 31, 2019	May 31, 2019	Mar. 31, 2018	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Nature of Business [Line Items]
Accumulated deficit				$ (311,971,000)		$ (277,535,000)		$ (311,971,000)		$ (277,535,000)
Cash, cash equivalents and short-term investments				88,000,000				88,000,000
Net loss				$ (20,018,000)			$ (15,478,000)	(34,436,000)	$ (26,504,000)
Cash in operations								$ 31,051,000	24,865,000
Net proceeds from sales of common stock									$ 10,513,000
ATM Program [Member] | H.C. Wainwright & Co., LLC [Member]
Nature of Business [Line Items]
Common stock aggregate offering price		$ 56,600,000
Percentage of gross proceeds from common stock sold through sales agreement		3.00%
Number of shares issued and sold								0
ATM Program [Member] | Leerink Partners LLC [Member]
Nature of Business [Line Items]
Common stock aggregate offering price			$ 50,000,000
Number of shares issued and sold					3,475,166
Net proceeds from sales of common stock	$ 21,600,000
Follow-on Public Offering [Member]
Nature of Business [Line Items]
Number of shares issued and sold						12,650,000				1,650,000
Common stock price per share						$ 6.75				$ 6.75
Net proceeds from sales of common stock						$ 80,100,000

Short-Term Investments - Summar

Short-Term Investments - Summary of Short-Term Investments (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 59,352	$ 89,568
Gross Unrealized Gains	34	5
Gross Unrealized Losses	(1)	(4)
Fair Value	59,385	89,569
U.S Government-Sponsored Enterprise Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	48,869	41,478
Gross Unrealized Gains	26	2
Gross Unrealized Losses	(1)	(3)
Fair Value	48,894	41,477
U.S. Treasury Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	10,483	48,090
Gross Unrealized Gains	8	3
Gross Unrealized Losses		(1)
Fair Value	$ 10,491	$ 48,092

Short-Term Investments - Additi

Short-Term Investments - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Investments Debt And Equity Securities [Abstract]
Realized gains (losses) on short-term investments	$ 0	$ 0	$ 0	$ 0
Other-than-temporary impairments recognized	$ 0	$ 0	$ 0	$ 0

Fair Value of Financial Asset_3

Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Liabilities:
Derivative liability	$ 3	$ 3
Fair Value, Measurements, Recurring [Member]
Assets:
Total assets	87,117	116,875
Liabilities:
Derivative liability	3	3
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member]
Assets:
Cash equivalents	27,732	26,806
Fair Value, Measurements, Recurring [Member] | U.S Government-Sponsored Enterprise Securities [Member]
Assets:
Short-term investments	48,894	41,477
Fair Value, Measurements, Recurring [Member] | U.S. Treasury Securities [Member]
Assets:
Cash equivalents		500
Short-term investments	10,491	48,092
Fair Value, Measurements, Recurring [Member] | Level 1 [Member]
Assets:
Total assets	27,732	26,806
Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Money Market Funds [Member]
Assets:
Cash equivalents	27,732	26,806
Fair Value, Measurements, Recurring [Member] | Level 2 [Member]
Assets:
Total assets	59,385	90,069
Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | U.S Government-Sponsored Enterprise Securities [Member]
Assets:
Short-term investments	48,894	41,477
Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | U.S. Treasury Securities [Member]
Assets:
Cash equivalents		500
Short-term investments	10,491	48,092
Fair Value, Measurements, Recurring [Member] | Level 3 [Member]
Liabilities:
Derivative liability	$ 3	$ 3

Fair Value of Financial Asset_4

Fair Value of Financial Assets and Liabilities - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Transfer of assets from level 1 to level 2	$ 0	$ 0
Transfer of assets from level 2 to level 1	0	0
Transfer of liabilities from level 1 to level 2	0	0
Transfer of liabilities from level 2 to level 1	$ 0	0
Fair value determination model	Monte-Carlo simulation analysis
Fair value of derivative liability	$ 0	$ 0

Prepaids and Other Current As_3

Prepaids and Other Current Assets - Schedule of Prepaids and Other Current Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Prepaid Expense And Other Assets Current [Abstract]
Prepaid clinical, manufacturing and scientific expenses	$ 1,741	$ 1,660
Prepaid insurance expenses	691	108
Other prepaid expenses and other current assets	634	713
Prepaids and other current assets	$ 3,066	$ 2,481

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Payables And Accruals [Abstract]
Accrued payroll and related expenses	$ 1,992	$ 2,746
Accrued research and development expenses	4,349	1,965
Accrued professional fees	443	799
Accrued other	79	151
Total accrued expenses	$ 6,863	$ 5,661

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)	Feb. 01, 2019	Feb. 01, 2018	Feb. 03, 2016	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares issued						2,543
Stock-based compensation				$ 1,021,000	$ 1,153,000	$ 1,991,000	$ 2,375,000
Stock option grants						1,497,200
Conversion of stock, shares converted	163,425
RSUs outstanding				4,598,850		4,598,850		3,158,676
Grant date fair value of options						$ 4,400,000
Weighted average grant date fair value						$ 2.92
Requisite service period						4 years
Issuance of common stock pursuant to employee stock purchase plan, shares						2,543
Proceeds from issuance of common stock related to at-the-market offering program, net							10,513,000
Bonus Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation						$ 100,000	$ 200,000
RSUs vested						163,425	0
RSUs outstanding				0		0
Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option grants						0
Number of options unvested				83,250		83,250
Nonemployees [Member] | Prior to 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option issued to purchase common stock						203,964
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of common stock related to at-the-market offering program, net						$ 100,000
Intrinsic value of options exercised				$ 100,000		$ 100,000
Maximum [Member] | Bonus Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation					$ 100,000
Awards requisite service period date		Feb. 1, 2019
Minimum [Member] | Bonus Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards requisite service period date		Feb. 1, 2018
2016 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance			1,581,839	752,490		752,490
Common stock reserved for issuance, percentage of number of shares of common stock outstanding			3.00%
Unrecognized compensation cost related to the unvested stock-based awards				$ 6,900,000		$ 6,900,000
Compensation cost not yet recognized, period for recognition						2 years 7 months 24 days
2016 Plan and 2008 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance				5,351,340		5,351,340
2016 ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance			138,757	502,681		502,681
Common stock reserved for issuance, percentage of number of shares of common stock outstanding			1.00%
Common stock available for issuance									138,757
Number of shares issued						22,615
Issuance of common stock pursuant to employee stock purchase plan, shares						22,615
2016 ESPP [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation				$ 100,000		$ 100,000

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Detail) - Bonus Restricted Stock Units (RSUs) [Member] - $ / shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Number of Shares
Unvested balance at December 31, 2018	163,425
Vested	(163,425)	0
Weighted Average Grant Date Fair Value
Unvested balance at December 31, 2018	$ 3.20
Vested	$ 3.20

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock-Based Compensation Expense, Including Shares Issued to Nonemployee for Consulting Services (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Stock-based compensation expense	$ 1,021	$ 1,153	$ 1,991	$ 2,375
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Stock-based compensation expense	399	412	769	775
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Stock-based compensation expense	$ 622	$ 741	$ 1,222	$ 1,600

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Number of Shares
Outstanding at December 31, 2018	3,158,676
Granted	1,497,200
Exercised	(2,543)
Forfeited	(54,483)
Outstanding at June 30, 2019	4,598,850	3,158,676
Exercisable at June 30, 2019	2,126,163
Vested and expected to vest at June 30, 2019	4,515,600
Weighted Average Exercise Price Per Share
Outstanding at December 31, 2018	$ 5.93
Granted	4.08
Exercised	1.09
Forfeited	8.01
Outstanding at June 30, 2019	5.30	$ 5.93
Exercisable at June 30, 2019	6.20
Vested and expected to vest at June 30, 2019	$ 5.36
Weighted Average Remaining Contractual Term, Outstanding	7 years 10 months 17 days	7 years 6 months 10 days
Weighted Average Remaining Contractual Term, Exercisable at June 30, 2019	6 years 9 months 7 days
Weighted Average Remaining Contractual Term, Vested and expected to vest at June 30, 2019	7 years 11 months 26 days
Aggregate Intrinsic Value, Outstanding		$ 471

Significant Agreements - Additi

Significant Agreements - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended	6 Months Ended
	Feb. 28, 2019	Nov. 30, 2014	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2014
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue			$ 843	$ 5,000	$ 1,785
Genentech [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Nonrefundable cash payment				5,000		$ 5,000
Future milestone payment						$ 96,000
Revenue				$ 5,000
Upfront payment received	$ 5,000
Astellas Collaboration Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue			$ 800		$ 1,800
Convertible promissory notes							$ 5,000
Initial research term		3 years 6 months
Description of material promises under agreement				(1) the research license; (2) the research services to be provided over the research term; and (3) participation in the Joint Research Committee (the “Committee”) to be provided over the research term of the agreement.
Astellas Collaboration Agreement [Member] | Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development and sales milestone payments		$ 398,500

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Federal income tax benefit	$ 0	$ 0	$ 0	$ 0
State income tax benefit	$ 0	$ 0	$ 0	$ 0

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of Basic and Diluted Net Loss per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Numerator:
Net loss	$ (20,018)	$ (15,478)	$ (34,436)	$ (26,504)
Denominator:
Weighted average common shares outstanding—basic and diluted	51,097,456	36,009,109	51,037,514	35,245,796
Net loss per share—basic and diluted	$ (0.39)	$ (0.43)	$ (0.67)	$ (0.75)

Net Loss per Share - Schedule_2

Net Loss per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted-average Shares Outstanding (Detail) - shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding	4,598,850	3,530,135
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding	4,598,850	3,346,629
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities outstanding		183,506

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018	Jan. 19, 2018
Leases [Abstract]
Operating lease, initial term			10 years
Operating lease, option to extend additional term			7 years
Operating lease expiration date	2018-05
Operating lease assets	$ 13,246	$ 13,849

Leases - Elements of Lease Expe

Leases - Elements of Lease Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Lease cost
Operating lease cost	$ 459	$ 662	$ 921	$ 1,322
Variable lease cost	179	163	316	309
Total lease cost	$ 638	$ 825	1,237	1,631
Other information
Operating cash flows used for operating leases			836	461
Operating lease liabilities arising from obtaining right-of-use assets			$ 13,738	$ 14,746
Weighted-average remaining lease term	8 years 10 months 2 days	9 years 10 months 2 days	8 years 10 months 2 days	9 years 10 months 2 days
Weighted-average discount rate	4.50%	4.50%	4.50%	4.50%

Leases - Schedule of Future Lea

Leases - Schedule of Future Lease Payments under Noncancelable Leases (Detail) $ in Thousands	Jun. 30, 2019USD ($)
Leases [Abstract]
2019	$ 851
2020	1,733
2021	1,780
2022	1,829
2023	1,880
Thereafter	8,757
Total lease payments	16,830
Less: imputed interest	(3,092)
Total operating lease liabilities	$ 13,738